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Dr Gabriel Aldea (Seattle, Wash). This is an important and
emerging topic, the incidence and significance of concomitant
MR in the presence of aortic stenosis. I have 2 brief comments
and several questions, and I will ask them sequentially.
The first comment is that you have shown these are coexistent
conditions, and aortic stenosis and MR are common. In fact,
28% of your original 802 patients had a concomitant mitral valve
surgery. That is a high incidence that supports a bias and institu-
tional belief that many of us have that severe residual MR ad-
versely affects survival and should be surgically addressed.
The second brief comment is, as you noted, we are dealing with
significant multiple overlapping pathologies that are confounding,
such as ischemic MR that can be seen in patients with CABG,
which may be reversible, and you are trying to sort out functional
MR from diseased mitral valve with primary pathology of the an-
nulus, leaflet, and cords. These are difficult to sort out, but you
managed to do this in your study by isolating patients with pure
aortic stenosis and specifically those without other mitral valve pa-
thology, and in those patients, the 56 (12%) of the 462 with mod-
erate or more MR, the magnitude of improvement when present
was modest. This observation mirrors what we now know from
the TAVR trials.
My first question is a methodological question. You have as-
sessed the impact of AVR on residual MR in the operating room.
I can see the logic and expediency of this, but what are the differ-
ences that you would expect with longer-term follow-up with se-
rial echocardiographic studies without the impact of immediate
postoperative changes and general anesthesia?
DrKaczorowski. In terms of longer-term follow-up, there are 2
studies in the literature that have looked at this retrospectively and
on a smaller scale. When looking at patients at least 1 year out, ac-
cording to an article published in The Annals of Thoracic Surgery
in 2007 and a more recent article published in The Journal of Tho-
racic and Cardiovascular Surgery with a longer-term follow-up,
significant changes were not observed in the proportion of
patients who experienced improvement in MR. It is an important
issue because there are 2 potential mechanisms that could be at
work. One is immediate relief of the pressure gradient across the
aortic valve. The second is longer-term remodeling that might
occur with the left ventricle, which might result in improvement
in the MR. These observations argue that the relief of the pressure
gradient across the aortic valve is probably more important thanrdiovascular Surgery c Volume 145, Number 2 347
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Dthe longer-term remodeling in terms of improvement in the MR.
You alluded to some of the data that have been reported in the
TAVR literature, and I think that is also what was seen in those re-
ports. I am aware of 2 studies that looked at change in MR in the
TAVR literature, and the immediate changes were not much differ-
ent than the longer-term changes. In these studies, MR was mea-
sured immediately postoperatively and then approximately 1
month afterward, and the investigators found that there were no
changes over that period of time. In the longer term, there is not
as much change as you might expect from ventricular remodeling,
and a good amount of the change is due to relief of that pressure
gradient across the aortic valve.
Dr Aldea. The second question is a mechanistic question. You
and others have noted that the presence of MR in a variety of sit-
uations, preceding and after CABG and now preceding AVR, has
a significant negative impact on long-term survival. You have also
shown that AV gradient does not correlate with the modest im-
provement in MR even if that is present. Given that, does the pres-
ence of nonstructural MR in the presence of symptomatic aortic
stenosis reflect the advanced underlying pathology or chronicity
or does it reflect other primary mitral valve issues? This is impor-
tant because you might be looking at the wrong parameters. Pa-
rameters of diastolic dysfunction might correlate more than
simply AV gradients. Ejection fraction and left atrial size may cor-
relate better with impact or lack therefore of AVR on MR.
Dr Kaczorowski. It is difficult to know, but I think we can say,
according to the mitral repair literature, that ongoing MR is cer-
tainly not a good thing. It leads to worse patient outcomes, and af-
ter mitral repair the persistence of MR has a detrimental effect on
patients. Repairing the MR seems to improve patient outcomes.
Data from studies on ischemic MR suggest that persistence of
some intermediate degrees of MR portends a worse long-term
prognosis. Whether repairing it makes a difference in that setting
is more difficult to sort out, but again, from what we know in the
literature, having ongoing long-standing MR is a bad thing. Ac-
cording to the mitral repair literature, repairing MR seems to mit-
igate some of those adverse effects of long-standing MR.
Dr Aldea. So let’s talk about that, which leads to the third clin-
ical question I have. Your conclusion suggests the more aggressive
medical approach even for moderate MR, particularly when it is
seen with concomitant aortic stenosis. This is a strong recommen-
dation and to actually broaden your presentation from a mere anal-
ysis of intraoperative echocardiographic MR associated with
AVR. You have an opportunity to sort that out because you can
analyze the immediate risk, the mortality, and the perioperative348 The Journal of Thoracic and Cardiovascular Surgmortality of the groups you have discussed (isolated AVR alone
compared with concomitant AVR and MV surgery) and look at
differences in survival over time. That is going to be particularly
important because it may affect the choice of therapy that is of-
fered to patients as we are looking at evolution of therapy choices
for surgical AVR surgery, surgical sutureless AVR, and transcath-
eter aortic valve surgery, as well as percutaneous mitral valve ap-
proaches, particularly in elderly and sick patients (eg, surgical
mitral valve repair, MitraClip with or without coronary sinus or
device intervention). I am interested to see how your data answer
the clinical relevance of residual MR in the presence of AS and
how minimal impact of AVR on MR is going to change your
group’s management recommendation, as a leading group in
TAVR nationally, in managing patients with aortic stenosis who
present with MR.
Dr Kaczorowski. Certainly. I think that more data are required
to answer that question. We do not have the mortality data that you
are asking about. What I can tell you is that the persistence of MR
portends aworse prognosis, and repairing it as we talked aboutmay
result in better patient outcomes. The approach to each of these pa-
tients has to be customized and dealt with on a per-patient basis.
That is, in a high-risk patient we know that double-valve surgery
carries greater operative risk. So patients who are at higher risk
and perhaps less likely to benefit may not be candidates for a dou-
ble-valve procedure, whereas younger healthier patients may be
more appropriate candidates to pursue the MR in this setting.
Moderator. Okay, Richard, 1 question.
Richard Shemin (Los Angeles, Calif). Okay, how about a yes or
no:Were these preoperative and postoperative measurements done
under anesthesia in the operating room or what were the time
points?
Dr Kaczorowski. I cannot give you a yes or no for that, but I
can tell you the preoperative echocardiograms were done within
6 months of the procedure. The postoperative echocardiogram
was done in the operating room. It was typically the immediate
postoperative transesophageal echocardiogram.
Dr Shemin. So we know that has a significant error rate. How
many of those patients actually went on to mitral valve repair or
replacement in follow-up?
Dr Kaczorowski. I do not have those data for you.
Dr Shemin. Do you measure the left atrial size and the mitral
valve annular size in your predictive model?
Dr Kaczorowski.We have the left atrial size, but I do not know
if we have the annular dimensions.
Dr Shemin. See? One question, 3 parts.ery c February 2013
